SYS-6010

This clinical study is divided into two phases, aiming to comprehensively evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity and efficacy of SYS6010 in subjects with advanced solid tumors. The first phase is the exploration phase of different dosing regimens (escalation phase), the main goal of which is to evaluate the safety and tolerability of SYS6010, determine its maximum tolerated dose (MTD) (if any) and the recommended dose for Phase II (RP2D). Secondary objectives include evaluating the pharmacokinetic characteristics, immunogenicity and preliminary efficacy of SYS6010. The second phase is the dose expansion phase, the main goal of which is to evaluate the efficacy of SYS6010 in specific subjects with advanced solid tumors under the dosing regimen determined in the previous exploration. Secondary objectives include evaluating other efficacy indicators, safety and tolerability, pharmacokinetic characteristics and immunogenicity of SYS6010 in specific subjects with advanced solid tumors under the dosing regimen determined in the previous exploration.